REG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan
30/10/2024 15:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241030:nRSd2818Ka&default-theme=true
RNS Number : 2818K Diaceutics PLC 30 October 2024
Diaceutics PLC
PDMR Shareholding/Share Incentive Plan
Belfast and London, 30 October 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry, has been
notified that on 30 October 2024, Global Shares Trustees (UK) Limited (the "UK
Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global
Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of
£0.002 in the capital of the Company ("Shares") on behalf of Susanne
Munksted, Jordan Clark, Nick Roberts and Jillian Beggs (PDMRs), in respect of
their purchase of Shares pursuant to the Company's UK and Global Share
Incentive Plan ("the SIP Schemes") for employees. These purchases will be
made each month until further notice.
In accordance with the SIP Schemes, the Company has matched these purchases
with a matched share award over an equivalent number of Shares purchased by
the employee, in the proportion of 1:1.
Enquiries:
Diaceutics PLC Tel: +44 (0)28 9040 6500
Nick Roberts, Chief Financial Officer investorrelations@diaceutics.com
Canaccord Genuity Limited (Nomad & Broker) Tel: +44 (0)20 7253 8000
Simon Bridges, Andrew Potts, Harry Rees
Alma Strategic Communications Tel: +44(0)20 3405 0205
Caroline Forde, Kinvara Verdon diaceutics@almastrategic.com
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Susanne Munksted
2 Reason for notification
a. Position/Status Chief Precision Medicine Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Global Share Incentive Plan
("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
118.379 p 122
Conditional share award:
Price(s) Volume(s)
Nil 122
e. Date of the transaction Share purchase and Conditional share award: 30 October 2024
f. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange
Conditional share award: Off-Market
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Jordan Clark
2 Reason for notification
a. Position/Status Chief Data Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
118.350 p 127
Matched share award:
Price(s) Volume(s)
Nil 127
e. Date of the transaction Share purchase and Matched Share award: 30 October 2024
f. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange
Matched Share Award: Off-Market
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Nick Roberts
2 Reason for notification
a. Position/Status Chief Finance Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
118.350 p 127
Matched share award:
Price(s) Volume(s)
Nil 127
e. Date of the transaction Share purchase and Matched Share award: 30 October 2024
f. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange
Matched Share Award: Off-Market
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Jillian Beggs
2 Reason for notification
a. Position/Status Chief Commercial Officer
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of
conditional share award over Shares under the Diaceutics plc UK Share
Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
118.350 p 127
Matched share award:
Price(s) Volume(s)
Nil 127
e. Date of the transaction Share purchase and Matched Share award: 30 October 2024
f. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange
Matched Share Award: Off-Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHQKKBPQBDDOKNRecent news on Diaceutics
See all newsREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan and TVR
AnnouncementREG - Diaceutics PLC - Notice of Results
AnnouncementREG - Diaceutics PLC - Block Listing Return
AnnouncementREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan and TVR
AnnouncementREG - Diaceutics PLC - PMx Promotional Partner Contract Enhancement
Announcement